|
業務類別
|
Biotechnology |
|
業務概覽
|
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue. |
| 公司地址
| 4 Kingsbury Avenue, Watertown, MA, USA, 02472 |
| 電話號碼
| +1 617 607-0800 |
| 傳真號碼
| +1 617 607-0530 |
| 公司網頁
| https://www.enanta.com |
| 員工數量
| 120 |
| Dr. Jay R. Luly, PhD |
Director, President and Chief Executive Officer |
美元 803.30K |
26/01/2026 |
| Dr. Scott T. Rottinghaus, M.D. |
Chief Medical Officer |
美元 560.30K |
26/01/2026 |
| Ms. Kathleen S. Capps, C.P.A. |
Executive Director, Accounting, Controller and Interim Principal Accounting Officer |
-- |
19/11/2025 |
| Mr. Harry R. Trout, III |
Vice President, Finance and Principal Financial Officer |
-- |
26/01/2026 |
| Mr. Brendan Luu |
Chief Business Officer |
-- |
26/01/2026 |
| Dr. Tara Lynn Kieffer, PhD |
Chief Product Strategy Officer |
-- |
26/01/2026 |
| Dr. Yat Sun Or, PhD |
Chief Scientific Officer |
美元 553.15K |
26/01/2026 |
| Mr. Matthew P. Kowalsky |
Chief Legal Officer and Corporate Secretary |
-- |
26/01/2026 |
|
|
| Dr. Jay R. Luly, PhD |
Director, President and Chief Executive Officer |
26/01/2026 |
| Mr. Terry C. Vance |
Independent Director |
26/01/2026 |
| Mr. Yujiro S. Hata |
Independent Director |
26/01/2026 |
| Mr. Mark G. Foletta |
Independent Director |
26/01/2026 |
| Ms. Kristine Peterson |
Independent Director |
26/01/2026 |
| Dr. Lesley Russell, M.R.C.P.,MB.Ch.B. |
Independent Director |
26/01/2026 |
| Dr. Bruce L.A. Carter,PhD |
Non-Executive Chairman of the Board |
26/01/2026 |
|
|
|
|
